Plain-English translation of NCT06542250 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This clinical trial is testing a new medication called , which is designed to help your immune system fight back against B-cell blood cancers that have returned or stopped responding to earlier treatments. The medication works by engaging your own T cells (a type of immune cell) to target and destroy cancer cells. Researchers want to learn whether this treatment is safe and effective for people like you.
Many patients with blood cancers like lymphoma and leukemia eventually develop cancers that no longer respond to standard treatments. This trial exists to find new options for people in that situation by testing whether this immune-based approach can offer hope when other therapies have failed.
You likely qualify if…
You likely don't qualify if…
You would visit the study center regularly to receive infusions of the medication and have your blood tested to monitor how your body is responding. The study has two phases: the first phase carefully identifies the safest dose of the medication, and the second phase tests whether that dose actually works against your cancer. Throughout the trial, researchers will track any side effects and measure whether your cancer is improving.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
United States